Head to Head Review: Novonesis A/S (NVZMY) and The Competition

Novonesis A/S (OTC:NVZMY) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Novonesis A/S to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.

Volatility & Risk

Novonesis A/S has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Novonesis A/S’s peers have a beta of 1.04, meaning that their average share price is 4% more volatile than the S&P 500.

Profitability

This table compares Novonesis A/S and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novonesis A/S	N/A	N/A	N/A
Novonesis A/S Competitors	-2,185.76%	-161.46%	-40.62%

Valuation & Earnings

This table compares Novonesis A/S and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Novonesis A/S	$2.60 billion	$439.08 million	38.15
Novonesis A/S Competitors	$578.61 million	-$71.15 million	-1.08

Novonesis A/S has higher revenue and earnings than its peers. Novonesis A/S is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Novonesis A/S and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novonesis A/S	1	0	0	0	1.00
Novonesis A/S Competitors	1877	5299	13714	290	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 93.64%. Given Novonesis A/S’s peers stronger consensus rating and higher possible upside, analysts plainly believe Novonesis A/S has less favorable growth aspects than its peers.

Institutional & Insider Ownership

0.0% of Novonesis A/S shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Novonesis A/S pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Novonesis A/S pays out 22.2% of its earnings in the form of a dividend. As a group, “Biological products, except diagnostic” companies pay a dividend yield of 2.6% and pay out 695.9% of their earnings in the form of a dividend.

Summary

Novonesis A/S peers beat Novonesis A/S on 8 of the 15 factors compared.

About Novonesis A/S

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.